Avanos Medical Inc has a consensus price target of $25.4, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from Keybanc, Stifel, and CL King on July 25, 2023, June 21, 2023, and May 22, 2023. With an average price target of $18.67 between Keybanc, Stifel, and CL King, there's an implied -5.29% downside for Avanos Medical Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|
The latest price target for Avanos Medical (NYSE: AVNS) was reported by Keybanc on July 25, 2023. The analyst firm set a price target for $0.00 expecting AVNS to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Avanos Medical (NYSE: AVNS) was provided by Keybanc, and Avanos Medical downgraded their sector weight rating.
There is no last upgrade for Avanos Medical.
The last downgrade for Avanos Medical Inc happened on July 25, 2023 when Keybanc changed their price target from N/A to N/A for Avanos Medical Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avanos Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avanos Medical was filed on July 25, 2023 so you should expect the next rating to be made available sometime around July 25, 2024.
While ratings are subjective and will change, the latest Avanos Medical (AVNS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Avanos Medical (AVNS) is trading at is $19.71, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.